| Identification | Back Directory | [Name]
Levemir (tn) | [CAS]
169148-63-4 | [Synonyms]
D04539
Levemir
Levemir (tn)
Insulin detemir
Levemir (tn) USP/EP/BP
Insulin detemir (usan/inn)
Insulin detemir (genetical recombination)
Recombinant Insulin Detemir protein (HEK293)
Insulin detemir (genetical recombination) (jan) | [Molecular Formula]
C267H402N64O76S6 | [MOL File]
169148-63-4.mol | [Molecular Weight]
5916.82 |
| Questions And Answer | Back Directory | [Preparation]
Levemir (tn) is produced through genetic engineering to generate insulin precursors, followed by subsequent protein modifications. It is primarily produced by the secretion and expression of recombinant Levemir (tn) precursors by Saccharomyces cerevisiae, which are then chemically modified with enzymatic cleavage and 14-carbon fatty acids to obtain the correctly conformated Levemir (tn). |
| Hazard Information | Back Directory | [Uses]
Antidiabetic. | [in vivo]
Insulin Detemir (d-INS) (5 IU/kg; i.p.; once daily; 2 weeks) demonstrates weight-sparing effects compared with other insulin formulations, and shows a intestinal tissues preference, potentially involving the activation of insulin/-catenin/CREB signaling pathways[1].
| Animal Model: | Obese type 2 diabetic db/db mice[1] | | Dosage: | 5 IU/kg | | Administration: | Intraperitoneal injection; once daily for 2 weeks | | Result: | Decreased body weight of the mice after 14-day daily injection of d-INS (5 IU/kg) significantly compared with those injected with the same dose of human Insulin or saline.
Induced rapid phosphorylation of protein kinase B (Akt) in the gut L cells of normal mice. |
|
|
|